Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN STORES TO OPEN 20 DRUGSTORES, 14 FOOD/DRUG

Executive Summary

AMERICAN STORES TO OPEN 20 DRUGSTORES, 14 FOOD/DRUG combo stores in 1986, the company declared in its just released annual report for 1985. "We intend to increase capital expenditures to the $280 mil. level in 1986 from $203 mil. last year, reflecting the acceleration of our new store development program," the chain added. Together with the four planned expanded food store openings, American Stores will open a total of 38 new stores in 1986. In 1985, the company opened five Jewel-Osco combo stores, nine Osco Drug Centers and nine Skaggs Alpha Beta combo stores, but closed 17 older stores for a net gain of six stores. American Stores noted that its previously announced plan to create a coast-to-coast drug chain under the Osco name continues to move ahead ("The Pink Sheet" May 20, 1985, p. 11). "All of the Skaggs Drug stores have been renamed as Osco, and the majority of the management and record systems have been consolidated at Osco corporate offices in Oak Brook, Illinois." According to the annual report, the final phase of the consolidation, expected to be completed by June, consists of merging Sav-on Drug into Osco. American Stores said that at the end of 1985 its Osco subsidiary operated 483 Osco stores in 29 states, plus 171 Sav-on Drug stores in California, for a total of 654 stores in 30 states "from Maine to California."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS010108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel